Device R&D
Sustaining Novo Nordisk’s leadership in protein drug delivery
Novo Nordisk is a world leader in combining protein research with the development of new delivery systems. In 1985, the launch of the NovoPen® insulin pen device pioneered this area. An immediate success, NovoPen® set a new standard in protein delivery. It ensured efficacy, safety and reliability while retaining a subtle and discreet appearance.
Since then, Novo Nordisk has developed more than 20 injection systems. They include durable, pre-filled and cartridges. Hence, the company has built up profound in-house experience in providing safe products and a solid understanding of user needs.
Novo Nordisk is committed to continuing its user-focused approach, and to making a difference in the lives of people relying on its products. Not only by engineering proteins into safe and effective therapies, but also by developing new and improved delivery systems for those proteins. We take this perspective into account from the outset, so that the protein can be optimally developed for convenient administration. Hence, Novo Nordisk undertakes parallel development of proteins and dedicated delivery systems.
Our leadership in user-friendly delivery systems continues as we explore new concepts for protein delivery. An array of innovative successors is in place for the products currently available. Novo Nordisk can thus quickly accommodate new user preferences or market dynamics and maintain its market position. Further, we pursue exploratory research into new forms of protein delivery that will further improve user convenience.
Read more about our insulin delivery systems
Read more about our growth hormone delivery systems
Se our other units in R&D
Diabetes Research Unit
Biopharmaceutical Research Unit
Global Development
Regulatory Affairs
CMC Supply
